---
title: "Thyroid Carcinoma Case Study: Lulu"
description: After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary metastasis
image: https://blog.fidocure.com/hubfs/lulu.jpg
---
[](https://www.fidocure.com/)
- [Veterinarians](https://fidocure.com/for-veterinarians/)
- [Portal Login](https://dvm.fidocure.com/)
- [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet)
- [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
- [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
- [Pet Parents](https://fidocure.com/pet-parents/)
- [About Us](https://fidocure.com/about-us/)
- [How it works](https://fidocure.com/how-it-works/)
- [Find a Clinic](https://fidocure.com/find-a-clinic/)
- [Contact Us](https://fidocure.com/contact-us/)
[Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
# Thyroid Carcinoma Case Study: Lulu
[Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post)
[Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.fidocure.com/fidocure-blog/thyroid-carcinoma-case-study-lulu) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.fidocure.com/fidocure-blog/thyroid-carcinoma-case-study-lulu) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.fidocure.com/fidocure-blog/thyroid-carcinoma-case-study-lulu)
#### After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary metastasis. Lulu has maintained a positive quality of life while in treatment and achieved extended time with her pet owners.**Lulu Rocha** is a **12-year-old female, spayed Akita Inu** who was originally diagnosed with** left thyroid carcinoma **following surgical excision in August 2017. Following this initial diagnosis, Lulu was monitored for disease recurrence at Veterinary Cancer Group (VCG). In June 2019, Lulu was presented to VCG for another palpable left cervical mass.
Imaging revealed a **2.8cm left cervical mass** adjacent to the previously excised left thyroid gland. Concurrently, the **right medial retropharyngeal lymph node **was noted to be mildly enlarged (3.5cm), likely due to compensatory hyperplasia. Surgical removal was elected. The cervical mass and the right medial retropharyngeal lymph node were excised completely with narrow margins.
Histopathology of the **left cervical mass revealed epithelial neoplasia of thyroid origin with moderate mitotic activity **(10 mitoses per 10 HPF). The neoplastic cells had effaced approximately 95% of the left cervical lymph node. Evaluation of the retropharyngeal lymph node revealed a reactive draining node with small hyperplastic follicles around the periphery and congested subcapsular and medullary sinuses. Both lymph nodes had been completely excised. These results were found to be consistent with metastatic thyroid carcinoma.
There was no evidence of intrathoracic metastatic disease on radiographs, although high potential for further metastasis was noted based on the pathology report.** Lulu's family did not opt to pursue traditional chemotherapeutic treatment** options and instead, in June 2019, elected to enroll in **FidoCure® .**
[**Read the rest of Lulu's story.**](https://fidocure.com/wp-content/uploads/2023/05/CaseStudy-Lulu.pdf)
## Related Articles
[](https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-case-study-missy)
[Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
### [Mammary Carcinoma Case Study: Missy](https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-case-study-missy)
#### After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.
[Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post)
[Read More](https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-case-study-missy)
[](https://blog.fidocure.com/fidocure-blog/lung-carcinoma-case-study-adley-hurwitz)
[Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
### [Lung Carcinoma Case Study: Adley Hurwitz](https://blog.fidocure.com/fidocure-blog/lung-carcinoma-case-study-adley-hurwitz)
#### After six months of FidoCure® enabled therapy, Adley showed no evidence of pulmonary mass recurrence.
[Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post)
[Read More](https://blog.fidocure.com/fidocure-blog/lung-carcinoma-case-study-adley-hurwitz)
- [How it Works](https://fidocure.com/how-it-works/)
- [FAQ](https://fidocure.com/faq/)
- [Contact Us](https://fidocurestg.wpengine.com/contact-us/)
- [For Vets](https://fidocure.com/for-veterinarians/)
- [About Us](https://fidocure.com/about-us/)
- [Terms of Service](https://fidocure.com/terms-of-service/)
- [Blog](https://blog.fidocure.com/fidocure-blog)
- [Careers](https://fidocure.com/careers/)
- [Privacy Policy](https://fidocure.com/privacy-policy/)
-
-
-
-
**FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2026 One Health Company, All rights reserved
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "Dr. Gerry Post",
"url" : "https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post"
},
"dateModified" : "2023-05-06T12:36:32.173Z",
"datePublished" : "2023-05-04T17:19:20.000Z",
"headline" : "Thyroid Carcinoma Case Study: Lulu",
"image" : [ "https://blog.fidocure.com/hubfs/lulu.jpg" ],
"mainEntityOfPage" : {
"@id" : "https://blog.fidocure.com/fidocure-blog/thyroid-carcinoma-case-study-lulu",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.fidocure.com/hubfs/fidocure_logo.png"
},
"name" : "FidoCure"
}
}
```